IVERIC bio Inc
Change company Symbol lookup
Select an option...
ISEE IVERIC bio Inc
HUN Huntsman Corp
IART Integra Lifesciences Holdings Corp
R Ryder System Inc
AAPL Apple Inc
IIM Invesco Value Municipal Income Trust
QQQ Invesco QQQ Trust
VZ Verizon Communications Inc
CHTR Charter Communications Inc
SPB Spectrum Brands Holdings Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Price
Delayed
$13.47
Day's Change
-0.015 (-0.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.52
Day's Low
13.16
Volume
(Light)

Today's volume of 630,136 shares is on pace to be much lighter than ISEE's 10-day average volume of 2,109,201 shares.

630,136

Company Profile

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
5.44x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2022
Current Month
6.6M
Previous Month
7.4M
Percent of Float
5.85%
Days to Cover
3.1407 Days

Share Information

ISEE is in a share class of common stock
Float
112.2M
Shares Outstanding
118.1M
Institutions Holding Shares
237
107.30%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Adrienne L. Graves
  • Pravin U. DugelPres.
  • Glenn P. SblendorioCEO
  • David Francis CarrollCFO
  • Keith WestbyCOO

Address

Insider Trading

During the most recent quarter, 25K shares were bought, and 272K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.